AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33334422 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline grade 3 diastolic dysfunction
Number of subjects: 1750
Study 33334422 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in diastolic dysfunction grade/grade 1 DD at 30 days
Number of subjects: 1750
Study 33334422 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental baseline grades of diastolic dysfunction
Number of subjects: 1750
Study 33334613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendrix® (4 separate 0.5 ml doses administered at 1 month, 2 months, and 6 months)
Number of subjects: 67
Study 33334613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendrix®
Number of subjects: 67
Study 33334730 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-based therapies
Number of subjects: 0
Study 33334730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas-FasL mediated off-target 'bystander' killing
Number of subjects: 0
Study 33334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity and β-cell function evaluated using HOMA of insulin sensitivity and estimates from oral glucose tolerance tests (Matsuda Index, insulinogenic index, C-peptide index, oral disposition index).
Number of subjects: 3108
Study 33334839 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS (text) messaging intervention involving reminders, psychoeducation, and check-ins
Number of subjects: 186
Study 33334839 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinical measures
Number of subjects: 186
Study 33334839 — intervention group
Group type: EXPERIMENTAL
Intervention: System-level outcomes
Number of subjects: 186
Study 33334839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 186
Study 33334839 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based surveys and qualitative interviews
Number of subjects: 186
Study 33334944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for patients with hypoxaemia and new infiltrates
Number of subjects: 12906
Study 33334944 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure (CHF)
Number of subjects: 12906
Study 33335322 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 full-dose booster (SD/SD D56; n=20)
Number of subjects: 62
Study 33335322 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 half-dose booster (SD/LD D56; n=32)
Number of subjects: 62
Study 33335322 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 open-label prime-boost (SD/SD D28; n=10)
Number of subjects: 62
Study 33335322 — intervention group
Group type: COMPARATOR
Intervention: MenACWY comparator vaccine (n=10)
Number of subjects: 62
Study 33335875 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33336184 — intervention group
Group type: EXPERIMENTAL
Intervention: Home wrist-worn accelerometry during normal routine for 72 hours.
Number of subjects: 20
Study 33336184 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluations including Fugl-Meyer (FM), Action Research Arm Test (ARAT), Wolf Motor Function Test (WMFT), Motor Activity Log (MAL), and hand motor subscale of the Stroke Impact Scale (SIS).
Number of subjects: 20
Study 33336184 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study 33336253 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry and whole genome sequencing (WGS)
Number of subjects: 0
Study 33336253 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 0
Study 33336283 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nebulization of acetylcysteine with salbutamol every 6 hours until end of invasive ventilation
Number of subjects: 72
Study 33336283 — intervention group
Group type: COMPARATOR
Intervention: On-demand nebulization of acetylcysteine or salbutamol applied on strict clinical indications only
Number of subjects: 72
Study 33336322 — intervention group
Group type: EXPERIMENTAL
Intervention: Reclassification based on PaO2/FIO2 ratios after 24 hours
Number of subjects: 689
Study 33336322 — intervention group
Group type: COMPARATOR
Intervention: Initial classification based on PaO2/FIO2 ratios
Number of subjects: 689
Study 33336372 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative conventional therapy (radiotherapy)
Number of subjects: 22
Study 33336538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fluid DNAH5 levels in ectopic pregnancy group
Number of subjects: 85
Study 33336538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fluid CK levels in ectopic pregnancy group
Number of subjects: 85
Study 33336538 — intervention group
Group type: COMPARATOR
Intervention: Cervical fluid DNAH5 levels in non-pregnant patients
Number of subjects: 85
Study 33336642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2
Number of subjects: 2791
Study 33336642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2 in children born to smoker mothers
Number of subjects: 2791
Study 33336642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational BMI increase of 5 kg/m2 in children born to non-smoker mothers
Number of subjects: 2791
Study 33337539 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (apixaban and rivaroxaban)
Number of subjects: 15678
Study 33337539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 15678
Study 33337539 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 15678
Study 33337539 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 15678
Study 33337539 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin
Number of subjects: 15678
Study 33337584 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual expert segmentation
Number of subjects: 394
Study 33337584 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated radiographic OA-based model segmentation
Number of subjects: 394
Study 33337584 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated HRC-based model segmentation
Number of subjects: 394
Study 33337584 — intervention group
Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (manual segmentation)
Number of subjects: 394
Study 33337584 — intervention group
Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (automated radiographic OA model)
Number of subjects: 394
Study 33337584 — intervention group
Group type: COMPARATOR
Intervention: Progressor cohort vs non-progressor cohort (automated HRC model)
Number of subjects: 394
Study 33337808 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise plans
Number of subjects: 170
Study 33337811 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy in nonelderly patients
Number of subjects: 682
Study 33337811 — intervention group
Group type: COMPARATOR
Intervention: Biologic therapy in elderly patients
Number of subjects: 682
Study 33337811 — intervention group
Group type: COMPARATOR
Intervention: Biologic withdrawal due to adverse events in elderly patients
Number of subjects: 682
Study 33337811 — intervention group
Group type: COMPARATOR
Intervention: Biologic withdrawal due to patient refusal in elderly patients
Number of subjects: 682
Study 33337937 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted frenectomy
Number of subjects: 0
Study 33337937 — intervention group
Group type: COMPARATOR
Intervention: Traditional frenectomy methods
Number of subjects: 0
Study 33338986 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT Out! Social Issue Theater intervention
Number of subjects: 1571
Study 33338986 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 1571
Study 33339120 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) treatment
Number of subjects: 24
Study 33339120 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) treatment
Number of subjects: 24
Study 33339120 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 24
Study 33339120 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA vs DHA
Number of subjects: 24
Study 33339120 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 24
Study 33339464 — intervention group
Group type: EXPERIMENTAL
Intervention: Children preparing to transition to oral feeding (CwTF)
Number of subjects: 0
Study 33339464 — intervention group
Group type: COMPARATOR
Intervention: Children with chronic illnesses
Number of subjects: 0
Study 33339512 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Work-Care model including person-centered dialogue meeting and increased collaboration
Number of subjects: 25
Study 33339512 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered dialogue meeting
Number of subjects: 25
Study 33339512 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between care manager, rehabilitation coordinator, and GP
Number of subjects: 25
Study 33339541 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI during the pandemic (2020)
Number of subjects: 6609
Study 33339541 — intervention group
Group type: COMPARATOR
Intervention: Door-to-balloon time and total ischemia times
Number of subjects: 6609
Study 33339541 — intervention group
Group type: COMPARATOR
Intervention: Mortality during the pandemic
Number of subjects: 6609
Study 33340064 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 33340064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33340402 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone levels <8.8 ng/ml on the day of ET
Number of subjects: 1205
Study 33340402 — intervention group
Group type: COMPARATOR
Intervention: Serum progesterone levels ≥8.8 ng/ml on the day of ET
Number of subjects: 1205
Study 33341314 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of malnutrition according to GLIM criteria
Number of subjects: 599
Study 33341314 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of nutritional status, particularly muscle status
Number of subjects: 599
Study 33341314 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urinary creatinine excretion rate (CER)
Number of subjects: 599
Study 33341407 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tobramycin (10 mg/kg/d, ≥10 days)
Number of subjects: 18
Study 33341409 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP cohort (mitral valve prolapse)
Number of subjects: 424
Study 33341409 — intervention group
Group type: COMPARATOR
Intervention: Non-MVP cohort
Number of subjects: 424
Study 33341409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MVP and non-MVP cohorts
Number of subjects: 424
Study 33341409 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ECV
Number of subjects: 424
Study 33341447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0
Study 33341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (serum levels <25 nmol/L)
Number of subjects: 1267
Study 33341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient vitamin D levels (serum levels >50 nmol/L)
Number of subjects: 1267
Study 33341448 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D levels (sufficient vs deficient) in resected stage I and II patients
Number of subjects: 1267
Study 33341448 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D levels in advanced PDAC
Number of subjects: 1267
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations for serotype Ia
Number of subjects: 38233
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations for serotype III
Number of subjects: 38233
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations ≥1.04 µg/mL for serotype Ia
Number of subjects: 38233
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord-blood IgG concentrations ≥1.53 µg/mL for serotype III
Number of subjects: 38233
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal sera IgG threshold ≥2.31 µg/mL for serotype Ia
Number of subjects: 38233
Study 33341870 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal sera IgG threshold ≥3.41 µg/mL for serotype III
Number of subjects: 38233
Study 33341883 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (emtricitabine 200 mg/tenofovir diphosphate 300 mg) administered for 12 weeks
Number of subjects: 40
Study 33342078 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pain medication
Number of subjects: 153
Study 33342228 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 84
Study 33342228 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-cap area measurement
Number of subjects: 84
Study 33342228 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage index measurement
Number of subjects: 84
Study 33342228 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered plaque assessment
Number of subjects: 84
Study 33342342 — intervention group
Group type: EXPERIMENTAL
Intervention: PACER (Progressive Aerobic Cardiovascular Endurance Run)
Number of subjects: 144
Study 33342342 — intervention group
Group type: EXPERIMENTAL
Intervention: CMSP (CHAMPS Motor Skills Protocol)
Number of subjects: 144
Study 33342342 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental promotion of more screen time
Number of subjects: 144
Study 33342342 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parent concern for children's safety
Number of subjects: 144
Study 33342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of lived experiences of long Covid patients through interviews and focus groups.
Number of subjects: 114
Study 33342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested quality principles for long Covid services.
Number of subjects: 114
Study 33342535 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic unilateral oophorectomy for fertility preservation
Number of subjects: 1
Study 33342535 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH analysis of ovarian cells
Number of subjects: 1
Study 33342535 — intervention group
Group type: EXPERIMENTAL
Intervention: IVG assay
Number of subjects: 1
Study 33343285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 46
Study 33343285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33343425 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-Based Telehealth Program
Number of subjects: 0
Study 33343483 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0
Study 33343498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor therapy
Number of subjects: 0
Study 33343498 — intervention group
Group type: COMPARATOR
Intervention: Motor therapy
Number of subjects: 0
Study 33343722 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus hypofractionated tomotherapy
Number of subjects: 52
Study 33343761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training delivered via mobile smoking cessation application (Craving to Quit, C2Q)
Number of subjects: 146
Study 33343761 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI's QuitSTART smoking cessation application (NCI)
Number of subjects: 146
Study 33343761 — intervention group
Group type: EXPERIMENTAL
Intervention: Written cessation materials (Materials)
Number of subjects: 146
Study 33344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil
Number of subjects: 44
Study 33344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg intravenously on days 1 and 15
Number of subjects: 44
Study 33344227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus tadalafil
Number of subjects: 44
Study 33344457 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics analysis of multiparametric magnetic resonance imaging (MRI)
Number of subjects: 0
Study 33344496 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess intake of energy and saturated fat
Number of subjects: 0
Study 33344496 — intervention group
Group type: COMPARATOR
Intervention: PNPLA3 genotype
Number of subjects: 0
Study 33344717 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous cervical VNS (tcVNS), n = 13
Number of subjects: 25
Study 33344717 — intervention group
Group type: COMPARATOR
Intervention: Sham device, n = 12
Number of subjects: 25
Study 33344752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone (2 mg, 4 mg, 6 mg, and 10 mg) administered once-per-week for 12 weeks
Number of subjects: 24
Study 33344752 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once-per-week for 12 weeks
Number of subjects: 24
Study 33344752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone (various dosages)
Number of subjects: 24
Study 33344752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allopregnanolone
Number of subjects: 24
Study 33344885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural grid electrode implantation
Number of subjects: 110
Study 33344885 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to Brain Trauma Foundation guidelines
Number of subjects: 110
Study 33345059 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 90 seconds to 12 minutes, 2-4 sessions/week for 16 weeks
Number of subjects: 0
Study 33345059 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Training (HIT-RT) - single set resistance training to muscular failure, 2-3 sessions/week for 16 weeks
Number of subjects: 0
Study 33345059 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not provided)
Number of subjects: 0
Study 33345095 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods; specific dosage and duration not available.
Number of subjects: 0
Study 33345095 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific intervention not available.
Number of subjects: 0
Study 33345115 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33345336 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone therapy
Number of subjects: 93
Study 33345620 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted educational and communication skills intervention
Number of subjects: 74
Study 33345620 — intervention group
Group type: COMPARATOR
Intervention: Telephone surveys and focus group interviews
Number of subjects: 74
Study 33345877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin
Number of subjects: 847
Study 33345934 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal gestational weight gain goal consistent with Institute of Medicine recommendations
Number of subjects: 6727
Study 33345934 — intervention group
Group type: COMPARATOR
Intervention: Discussion of gestational weight gain goals with provider
Number of subjects: 6727
Study 33345967 — intervention group
Group type: EXPERIMENTAL
Intervention: Invu system (wireless, wearable, self-administered device)
Number of subjects: 147
Study 33346007 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI therapy (pantoprazole 40 mg once daily for 4 weeks)
Number of subjects: 75
Study 33346007 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI withdrawal in FD-stoppers
Number of subjects: 75
Study 33346007 — intervention group
Group type: COMPARATOR
Intervention: PPI therapy in HVs
Number of subjects: 75
Study 33346007 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of dyspeptic symptoms with eosinophils
Number of subjects: 75
Study 33346007 — intervention group
Group type: COMPARATOR
Intervention: Increased eosinophils and permeability in HVs on PPIs
Number of subjects: 75
Study 33346365 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticoids (28.9%)
Number of subjects: 2798
Study 33346365 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart disease presence
Number of subjects: 2798
Study 33346365 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart disease patients
Number of subjects: 2798
Study 33346365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in heart disease patients
Number of subjects: 2798
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) prescribed in 28.3% of cases; 90.2% of patients with UGI bleeding received PPI.
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy for 6-12 months after elective PCI.
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UGI bleeding and thrombotic events.
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: History of peptic ulcer disease.
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosion of the upper gastrointestinal tract.
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure (HF).
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aortic aneurysm (AAA).
Number of subjects: 934
Study 33346428 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery atherosclerosis (APA).
Number of subjects: 934
Study 33346476 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic coronary artery disease and diabetes mellitus
Number of subjects: 1023
Study 33346476 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m2)
Number of subjects: 1023
Study 33346476 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 1023
Study 33346510 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect cold atmospheric plasma (CAP) treatment for 3 months
Number of subjects: 14
Study 33346510 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect cold atmospheric plasma (CAP) treatment for 6 months
Number of subjects: 14
Study 33346510 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator's assessment of indirect CAP treatment
Number of subjects: 14